133 related articles for article (PubMed ID: 37651927)
21. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
Kim Y; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Cancer Res Treat; 2019 Apr; 51(2):502-509. PubMed ID: 29898592
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A
BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
Imai H; Kaira K; Suzuki K; Anzai M; Tsuda T; Ishizuka T; Kuwako T; Naruse I; Nemoto K; Uchino J; Morozumi N; Ishihara S; Minato K; Hisada T
Lung Cancer; 2018 Dec; 126():41-47. PubMed ID: 30527191
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.
Chiu LC; Hsu PC; Wang CC; Ko HW; Kuo SC; Ju JS; Tung PH; Huang AC; Yang CT
Thorac Cancer; 2024 Mar; 15(7):529-537. PubMed ID: 38279515
[TBL] [Abstract][Full Text] [Related]
26. Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
Jiang Z; Zhang J; Sun H; Wang C; Zhang Y; Li Y; Pan Z
Thorac Cancer; 2021 Sep; 12(17):2369-2374. PubMed ID: 34255422
[TBL] [Abstract][Full Text] [Related]
27. A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632.
Noro R; Igawa S; Bessho A; Hirose T; Shimokawa T; Nakashima M; Minato K; Seki N; Tokito T; Harada T; Sasada S; Miyamoto S; Tanaka Y; Furuya N; Kaburagi T; Hayashi H; Iihara H; Okamoto H; Kubota K
Lung Cancer; 2021 Nov; 161():49-54. PubMed ID: 34536731
[TBL] [Abstract][Full Text] [Related]
28. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
Hirsh V
BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
[TBL] [Abstract][Full Text] [Related]
29. A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non-small cell lung cancer.
Huang CY; Huang HL; Lan CC; Huang YC; Wu YK
BMC Cancer; 2023 May; 23(1):413. PubMed ID: 37158884
[TBL] [Abstract][Full Text] [Related]
30. A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
Pham CP; Nguyen TTH; Do AT; Nguyen TK; Hoang TAT; Le TA; Vuong DTH; Nguyen DNT; Dang VK; Nguyen TO; Pham VL; Nguyen MH; Vo THT; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Nguyen KD; Nguyen HG; Truong CM; Pham TMC; Nguyen TBP
BMC Cancer; 2024 Feb; 24(1):176. PubMed ID: 38317094
[TBL] [Abstract][Full Text] [Related]
31. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
32. Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial.
Kobayashi N; Hashimoto H; Kamimaki C; Nagasawa R; Tanaka K; Kubo S; Katakura S; Chen H; Hirama N; Ushio R; Aoki A; Nakashima K; Teranishi S; Manabe S; Watanabe H; Horita N; Watanabe K; Hara Y; Yamamoto M; Kudo M; Piao H; Kaneko T
Thorac Cancer; 2020 Aug; 11(8):2125-2129. PubMed ID: 32495514
[TBL] [Abstract][Full Text] [Related]
33. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
[TBL] [Abstract][Full Text] [Related]
34. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
Cancer Res Treat; 2023 Apr; 55(2):479-487. PubMed ID: 36596729
[TBL] [Abstract][Full Text] [Related]
35. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
Chen C; Zhang C; Lin H; Liu Q; Wu L; Zhou C; Zhang J
Ther Adv Chronic Dis; 2022; 13():20406223221125706. PubMed ID: 36274751
[TBL] [Abstract][Full Text] [Related]
36. A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation.
Lee Y; Kim HR; Hong MH; Lee KH; Park KU; Lee GK; Kim HY; Lee SH; Lim KY; Yoon SJ; Cho BC; Han JY
Cancer; 2023 Feb; 129(3):405-414. PubMed ID: 36451343
[TBL] [Abstract][Full Text] [Related]
37. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell
Lung Cancer Patients with Acquired EGFR T790M Mutation].
Gu Y; Tian X; Wang R; Li X; Qian K; Li Y; Nong J
Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):843-851. PubMed ID: 36617470
[TBL] [Abstract][Full Text] [Related]
39. Tislelizumab plus chemotherapy for patients with
Zhong H; Zhang X; Tian P; Chu T; Guo Q; Yu X; Yu Z; Li Y; Chen L; Liu J; Zhang Y; Guan Y; Shi X; Wang J; Zhao Y; Han B
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597849
[TBL] [Abstract][Full Text] [Related]
40. REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis.
Hou B; Lu X; Gao DC; Liu QX; Zhou D; Zheng H; Dai JG
Pak J Pharm Sci; 2021 Jul; 34(4):1459-1468. PubMed ID: 34799322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
